TY - JOUR
T1 - Patients' Knowledge about Prescribed Antipsychotics and Medication Adherence in Schizophrenia
T2 - A Cross-Sectional Survey
AU - Nagai, Nobuhiro
AU - Tani, Hideaki
AU - Suzuki, Takefumi
AU - Ikai, Saeko
AU - Gerretsen, Philip
AU - Mimura, Masaru
AU - Uchida, Hiroyuki
N1 - Funding Information:
Dr. Nagai has received manuscript fees from Dainippon Sumitomo within the past 3 years. Dr. Tani has received grants or manuscript fees from Eli Lilly and Sumitomo Dainippon Pharma within the past 3 years. Dr. Suzuki has received manuscript or speaker’s fees from Astellas, Dainippon Sumitomo Pharma, Eli Lilly, Elsevier Japan, Janssen Pharmaceuticals, Meiji Seika Pharma, Novartis, Otsuka Pharmaceuti-?al, W?ley Japan, and Yosht om? Y akuh?n w?th?n the past 3 years. Dr. Ikai has received manuscript fees or speaker’s honoraria from Dainippon Sumitomo and Otsuka within the past 3 years. Dr. Gerretsen has received fellowship awards from the Canadian Institutes of Health Research (CIHR), Ontario Mental Health Foundation, and Centre for Addiction and Mental Health Foundation. Dr. Mimura has received grants and/or speaker’s honoraria from Asahi Kasei Pharma, Astellas Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Meiji-Seika Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Otsuka Pharma?eut??al, Pfizer, Shonog? T akeda, Tanabe Mt sub?sh? Pharma, and Yoshitomi Yakuhin within the past 3 years. Dr. Uchida has received grants from Astellas Pharmaceutical, Eisai, Otsuka Pharmaceutical, Shionogi, Dainippon-Sumitomo Pharma, Eli Lilly, Mochida Pharmaceutical, Meiji-Seika Pharmaceutical, and Novartis; speaker’s honorar?a from Otsuka Pharma?eut??al, El? L?lly, Sh?onog?, Pfizer, Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, MSD, and Janssen Pharmaceutical; and advisory panel payments from Dainippon-Sumitomo Pharma within the past 3 years.
Funding Information:
This research was funded by the Inokashira Hospital Grant for Psychiatry Research.
Publisher Copyright:
© Georg Thieme Verlag KG Stuttgart - New York.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Introduction Data on the knowledge about antipsychotic medications prescribed in patients with schizophrenia are very limited. Moreover, it remains unclear how patients' knowledge about prescribed antipsychotics affects medication adherence. Methods ighty-one Japanese outpatients with schizophrenia according to the International Classification of Diseases, 10th edition, were included. Patients' knowledge of the primary antipsychotics prescribed to them in terms of therapeutic effects, type, and implicated neurotransmitters was assessed with a multiple-choice questionnaire developed for this study. Medication possession ratios (MPRs) were compared between patients who answered correctly and those who did not in each category. Results The percentages of subjects who answered correctly regarding antipsychotic effects, type, and implicated neurotransmitters were low at 30.9%, 30.9%, and 7.4%, respectively. No differences were found in MPRs between subjects who answered correctly and those who did not. Discussion Our preliminary results indicate that patients lack knowledge about their antipsychotic medications. More concerning, they suggest that knowledge about prescribed antipsychotics may not directly translate into actual medication adherence in patients with schizophrenia.
AB - Introduction Data on the knowledge about antipsychotic medications prescribed in patients with schizophrenia are very limited. Moreover, it remains unclear how patients' knowledge about prescribed antipsychotics affects medication adherence. Methods ighty-one Japanese outpatients with schizophrenia according to the International Classification of Diseases, 10th edition, were included. Patients' knowledge of the primary antipsychotics prescribed to them in terms of therapeutic effects, type, and implicated neurotransmitters was assessed with a multiple-choice questionnaire developed for this study. Medication possession ratios (MPRs) were compared between patients who answered correctly and those who did not in each category. Results The percentages of subjects who answered correctly regarding antipsychotic effects, type, and implicated neurotransmitters were low at 30.9%, 30.9%, and 7.4%, respectively. No differences were found in MPRs between subjects who answered correctly and those who did not. Discussion Our preliminary results indicate that patients lack knowledge about their antipsychotic medications. More concerning, they suggest that knowledge about prescribed antipsychotics may not directly translate into actual medication adherence in patients with schizophrenia.
KW - adherence
KW - antipsychotics
KW - knowledge
KW - medication
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85021932320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021932320&partnerID=8YFLogxK
U2 - 10.1055/s-0043-113828
DO - 10.1055/s-0043-113828
M3 - Article
C2 - 28675911
AN - SCOPUS:85021932320
VL - 50
SP - 264
EP - 269
JO - Pharmakopsychiatrie und Neuropsychopharmakologie
JF - Pharmakopsychiatrie und Neuropsychopharmakologie
SN - 0176-3679
IS - 6
ER -
